-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Since July, the resignation of pharmaceutical industry companies has continued, including Puluo Pharmaceuticals, Xinhua Pharmaceuticals, Hengrui, e.
, among which there are many positions such as general managers and deputy general manage.
General Managers and Deputy General Managers of Several Companies Resigned On July 22, Huaren Pharmaceutical's board of directors received a resignation report from the company's CEO, Bu Guox.
Bu Guoxiu applied for his resignation as CEO due to personal reasons, and will no longer hold other positions in the company and its subsidiaries after his resignati.
According to the company's annual report disclosed in 2021, the total pre-tax remuneration received by Bu Guoxiu from the company was 3333 million yu.
Puluo Pharmaceutical announced on July 15 that the company's board of directors received a written resignation report submitted by the company's deputy general manager Tang Erqi.
Tang Erqing applied to resign from the position of deputy general manager of the company due to personal reasons, and will no longer hold any position in the company after his resignati.
The company's annual report disclosed in 2021 shows that Tang Erqing's total pre-tax remuneration from the company is 810,000 yu.
On July 7, Future Medical announced that the company's board of directors recently received written resignation reports from director .
Lu Fenqi and general manager .
Fan Shaof.
.
Lu Fenqi and .
Fan Shaofei both resigned due to personal reaso.
After resigning, both of them no longer hold any positions in the compa.
On July 4, Xinmai Medical announced that the company's board of directors recently received a resignation report from deputy general manager Jin Guoche.
Jin Guocheng applied for his resignation due to personal reaso.
After his resignation, Jin Guocheng will no longer hold any positions in Cardiovascular Medici.
As of now, Jin Guocheng does not directly hold shares in Xinmai Medic.
The 2021 annual report shows that Jin Guocheng will receive 1671 million pre-tax remuneration from Xinmai Medical in 202Xinhua Pharmaceutical announced on the evening of July 1 that the board of directors of the company received a written resignation report submitted by the company's director and general manager, .
Du Deping, on July 1, 202.
Du Deping resigned due to job change and no longer holds any position in the company after his resignati.
As of the disclosure date of this announcement, .
Du Deping holds about 180,000 A shares of the compa.
The environment of the pharmaceutical industry is changi.
Judging from the reasons for the resignation of executives of pharmaceutical companies, the main reasons are personal reaso.
At the same time, it can also be seen that the policy environment of the pharmaceutical industry has changed and the adjustment of executives within the company has accelerat.
For example, Guangyuyuan has resigned 6 executives this year, and the industry believes that this is related to the company's structural adjustme.
Not long ago, Shanxi Guangyuyuan, a subsidiary of Guangyuyuan, changed its business scope by adding drug Internet information servic.
At the same time, the original production, processing and sales of traditional Chinese medicine pieces were not within its business sco.
From the perspective of the overall environment of Chinese patent medicines, the centralized procurement of Chinese patent medicines has been regarded as a major trend in recent years, and local governments are actively carrying out centralized procurement, including Shandong and Guangdong provinc.
However, the normalization of centralized procurement will still have a profound impact on the Chinese patent medicine indust.
Baiyunshan mentioned in a recent survey that the Guangdong Inter-Provincial Alliance, the Hubei Inter-Provincial Alliance, and the Shandong Inter-Provincial Alliance have successively carried out the procurement of Chinese patent medicines or Chinese herbal decoction piec.
With the gradual rollout of the nationwide centralized procurement of Chinese patent medicines/traditional Chinese medicines, Chinese medicine enterprises will face certain challeng.
In this regard, the company also stated that in the future, it will actively participate in the state-organized bulk procurement bidding, and continuously increase the market share of related products; at the same time, it will further improve production and management efficiency, effectively reduce production costs, and enhance product competitivene.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, among which there are many positions such as general managers and deputy general manage.
General Managers and Deputy General Managers of Several Companies Resigned On July 22, Huaren Pharmaceutical's board of directors received a resignation report from the company's CEO, Bu Guox.
Bu Guoxiu applied for his resignation as CEO due to personal reasons, and will no longer hold other positions in the company and its subsidiaries after his resignati.
According to the company's annual report disclosed in 2021, the total pre-tax remuneration received by Bu Guoxiu from the company was 3333 million yu.
Puluo Pharmaceutical announced on July 15 that the company's board of directors received a written resignation report submitted by the company's deputy general manager Tang Erqi.
Tang Erqing applied to resign from the position of deputy general manager of the company due to personal reasons, and will no longer hold any position in the company after his resignati.
The company's annual report disclosed in 2021 shows that Tang Erqing's total pre-tax remuneration from the company is 810,000 yu.
On July 7, Future Medical announced that the company's board of directors recently received written resignation reports from director .
Lu Fenqi and general manager .
Fan Shaof.
.
Lu Fenqi and .
Fan Shaofei both resigned due to personal reaso.
After resigning, both of them no longer hold any positions in the compa.
On July 4, Xinmai Medical announced that the company's board of directors recently received a resignation report from deputy general manager Jin Guoche.
Jin Guocheng applied for his resignation due to personal reaso.
After his resignation, Jin Guocheng will no longer hold any positions in Cardiovascular Medici.
As of now, Jin Guocheng does not directly hold shares in Xinmai Medic.
The 2021 annual report shows that Jin Guocheng will receive 1671 million pre-tax remuneration from Xinmai Medical in 202Xinhua Pharmaceutical announced on the evening of July 1 that the board of directors of the company received a written resignation report submitted by the company's director and general manager, .
Du Deping, on July 1, 202.
Du Deping resigned due to job change and no longer holds any position in the company after his resignati.
As of the disclosure date of this announcement, .
Du Deping holds about 180,000 A shares of the compa.
The environment of the pharmaceutical industry is changi.
Judging from the reasons for the resignation of executives of pharmaceutical companies, the main reasons are personal reaso.
At the same time, it can also be seen that the policy environment of the pharmaceutical industry has changed and the adjustment of executives within the company has accelerat.
For example, Guangyuyuan has resigned 6 executives this year, and the industry believes that this is related to the company's structural adjustme.
Not long ago, Shanxi Guangyuyuan, a subsidiary of Guangyuyuan, changed its business scope by adding drug Internet information servic.
At the same time, the original production, processing and sales of traditional Chinese medicine pieces were not within its business sco.
From the perspective of the overall environment of Chinese patent medicines, the centralized procurement of Chinese patent medicines has been regarded as a major trend in recent years, and local governments are actively carrying out centralized procurement, including Shandong and Guangdong provinc.
However, the normalization of centralized procurement will still have a profound impact on the Chinese patent medicine indust.
Baiyunshan mentioned in a recent survey that the Guangdong Inter-Provincial Alliance, the Hubei Inter-Provincial Alliance, and the Shandong Inter-Provincial Alliance have successively carried out the procurement of Chinese patent medicines or Chinese herbal decoction piec.
With the gradual rollout of the nationwide centralized procurement of Chinese patent medicines/traditional Chinese medicines, Chinese medicine enterprises will face certain challeng.
In this regard, the company also stated that in the future, it will actively participate in the state-organized bulk procurement bidding, and continuously increase the market share of related products; at the same time, it will further improve production and management efficiency, effectively reduce production costs, and enhance product competitivene.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
